Low dosage alpha-interferon treatment in patients with advanced cutaneous T-cell lymphoma.
Treatment with high dose (10-50 x 10(6) IU/m2 three times a week) of alpha-interferon (alpha-IFN) has been shown to induce remissions in about 50% of patients with cutaneous T-cell lymphoma. The optimal alpha-IFN dose, however, is not known. 4 patients with advanced cutaneous T-cell lymphoma were therefore treated with alpha-IFN in low doses of 2-4 x 10(6) IU/m2 three times a wk. 1 complete, 1 partial and 1 minor remission were observed. Skin biopsies before and during treatment were taken from 2 of the patients and showed improvement. Low doses of alpha-IFN can thus induce remission in patients with cutaneous T-cell lymphoma.
Hagberg
H
H
Department of Oncology, Akademiska Sjukhuset, Uppsala, Sweden.
Juhlin
L
L
Scheynius
A
A
Tjernlund
U
U
D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects; D008223:Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D007370:Interferon Type I